Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain
August 31, 2015 at 16:01 PM EDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands ...